A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

This study tests an advanced type of CAR T-cell therapy (a personalized immune treatment) for solid tumors that have a specific genetic feature — loss of a certain immune marker (HLA-A*02) — combined with expression of a protein called mesothelin. This therapy is designed to attack only cancer cells while sparing healthy tissue. **You may be eligible if...** - You were previously enrolled in the BASECAMP-1 screening study with confirmed tumor characteristics - You have advanced, unresectable, or metastatic colorectal, lung, pancreatic, ovarian, mesothelioma, or other solid tumors expressing mesothelin - You have already tried required prior therapies for your cancer type - You are in good overall health and have a life expectancy of at least 3 months **You may NOT be eligible if...** - You have not completed the required pre-screening (BASECAMP-1) process - You have significant organ dysfunction - You have active autoimmune disease or are on immune-suppressing drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.